RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 2, 2012
Released December 2012

Featuring interviews with Drs Leonard B Saltz, Suzanne George, Andrew X Zhu and Richard M Goldberg. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although non-CRC gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES
    • Counsel patients with Stage II colon cancer about their individual risk of recurrence based on clinical, pathologic and genomic biomarkers, and consider adjuvant therapeutic options based on an evaluation of this information.
    • Effectively apply the results of practice-changing clinical research to the selection and sequencing of chemobiologic regimens for patients with metastatic CRC.
    • Educate patients with unresectable metastatic neuroendocrine tumors of the GI tract regarding novel treatment approaches and their associated risks and benefits.
    • Evaluate therapeutic options — including surgery and the use of approved and novel kinase inhibitors — for patients with newly diagnosed gastrointestinal stromal tumors (GIST) and those with imatinib- and sunitinib-resistant GIST.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with advanced hepatocellular carcinoma.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT


    Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/GICU212/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SaltzAdvisory Committee: EMD Serono Inc, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Bristol-Myers Squibb Company, Genomic Health Inc, Genzyme Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, OSI Oncology; Paid Research: Amgen Inc, Merck and Company Inc. Dr GeorgeConsulting Agreement: Bayer HealthCare Pharmaceuticals; Research Grant: Bayer HealthCare Pharmaceuticals, Novartis Pharmaceuticals Corporation; Stock Ownership: Abbott Laboratories. Dr ZhuAdvisory Committee: Abbott Laboratories, Bristol-Myers Squibb Company, Eisai Inc, Sanofi. Dr GoldbergAdvisory Committee: Bayer HealthCare Pharmaceuticals; Consulting Agreements: Genomic Health Inc, Sanofi; Data and Safety Monitoring Board: Lilly USA LLC.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2012
    Expiration date: December 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Update, Issue 2, 2012
Released December 2012

Featuring interviews with Drs Leonard B Saltz, Suzanne George, Andrew X Zhu and Richard M Goldberg. (Text and Audio Content)

Read print: